Revance Therapeutics Inc (NASDAQ: RVNC)’s Outlook Shocks Bears.

In the last trading session, 1.81 million shares of the Revance Therapeutics Inc (NASDAQ:RVNC) were traded, and its beta was 1.15. Most recently the company’s share price was $3.64, and it changed around -$0.14 or -3.70% from the last close, which brings the market valuation of the company to $379.36M. RVNC currently trades at a discount to its 52-week high of $37.98, offering almost -943.41% off that amount. The share price’s 52-week low was $3.62, which indicates that the current value has risen by an impressive 0.55% since then. We note from Revance Therapeutics Inc’s average daily trading volume that its 3-month average coming to 1.77 million.

Revance Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.75. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended RVNC as a Hold, whereas 6 deemed it a Buy, and 0 rated it as Underweight. Revance Therapeutics Inc is expected to report earnings per share of $MARVION INC for the current quarter.

Revance Therapeutics Inc (NASDAQ:RVNC) trade information

Instantly RVNC has showed a red trend with a performance of -3.70% at the end of last trading. The performance over the last five days has remained in the red territory. The company’s shares are currently down -58.59% year-to-date, but still down -8.31% over the last five days. On the other hand, Revance Therapeutics Inc (NASDAQ:RVNC) is -29.87% down in the 30-day period.

The consensus price target as assigned by Wall Street analysts is $32, which translates to bulls needing to increase their stock price by 88.62% from its current value. Analyst projections state that RVNC is forecast to be at a low of $24 and a high of $37.

Revance Therapeutics Inc (RVNC) estimates and forecasts

Revance Therapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -58.16 percent over the past six months and at a 43.34% annual growth rate that is well above the industry average of 13.30%.

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 0.57%. Revance Therapeutics Inc earnings are expected to increase by 23.04% in 2024, but the outlook is positive 11.60% per year for the next five years.